Darktrace, a provider of enterprise cyber threat defense software, announced Wednesday that it has raised new growth equity financing, led by KKR, a leading global investment firm, with participation from existing investor Summit Partners, and new investors TenEleven Ventures and SoftBank-affiliated SB ISAT Fund.
Invoke Capital first identified Darktrace’s differentiated approach to cybersecurity threats and funded Darktrace in 2013, providing operational expertise since. Darktrace will use the funds to further accelerate the global roll-out of its award-winning Enterprise Immune System technology.
Darktrace is capable of identifying new, emerging threats within computer networks in real time including insider attacks, ransomware, machine-based attacks, and unknown threat scenarios.
Using advanced mathematics and machine learning techniques based on the biological principles of the human immune system, Darktrace addresses the challenge of detecting and responding to cyber threats that evade existing solutions.
The company is recognized as one of the UK’s most successful security startups, with founders including senior members of the UK government’s cyber community from MI5 and GCHQ.
“Securing the backing of another leading global investor like KKR is an important milestone for Darktrace and a strong validation of the technology we have developed,” said Nicole Eagan, CEO of Darktrace. “We chose to partner with KKR because of their unique global network to support our international expansion and rich history of enterprise building in the technology sector.”
